Since the first clinical trial conducted in 1985 (6), the therapeutic application of IFN-γ has been tested in a variety of malignancies, including melanoma, leukemia, ovarian cancer, renal cell carcinoma, hepatocellular carcinoma, lung cancer, breast cancer, bladder cancer and colorectal cancer (7). Here, IFNG is linked to melanoma.